Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 25Thoracic 18Lymphoid 7Breast 7Gynecologic 6Sarcoma 4Other solid neoplasm 4Other hematologic neoplasm 4Genitourinary 4CNS 4Head & Neck 3Dermatologic 3Tumor-Agnostic 1Myeloid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia, Myeloid, Acute 1

Interventions

Azacitidine 41Cytarabine 27fludarabine phosphate 25Cyclophosphamide 23venetoclax 21fludarabine 21Peripheral Blood Stem Cell Transplantation 20Mycophenolic Acid 17Filgrastim 17Decitabine 17Tacrolimus 16Whole-Body Irradiation 15ruxolitinib 14Cyclosporine 14Busulfan 14Melphalan 12Methotrexate 10Imatinib Mesylate 10Stem Cell Transplantation 9Antilymphocyte Serum 8Alemtuzumab 8nilotinib 7decitabine and cedazuridine drug combination 7Granulocyte Colony-Stimulating Factor 7Rituximab 6Injections 6Idarubicin 6Dasatinib 6Clofarabine 6AP 1903 reagent 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Drug Therapy × Myeloid × Clear all
NCT04764513 2022-03-28

Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT

Chinese PLA General Hospital

Phase 1/2 Unknown
20 enrolled
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡